Melanomas Resist T-cell Therapy Through Inflammation-induced Reversible Dedifferentiation

Melanomas resist T-cell therapy through inflammation-induced reversible dedifferentiation. Adoptive cell transfer therapies (ACTs) with cytotoxic T cells that target melanocytic antigens can achieve remissions in patients with metastatic melanomas, but tumours frequently relapse.